Costs of early adjuvant radiation therapy after radical prostatectomy: A decision analysis

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 701-706

  Showalter, T N ^a   Foley, K A ^b   Jutkowitz, E ^b   Lallas, C D ^a   Trabulsi, E J ^b   Gomella, L G ^a   Dicker, A P ^a   Pizzi, L T ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adjuvant radiation therapy; Cost effectiveness; Post; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER NECK STENOSIS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL OBSERVATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY INTERVENTION; FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; REIMBURSEMENT; SALVAGE THERAPY;

EID: 82455180650     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr281     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low-risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-S19.
3. Mariotto AB, Yabroff KR, Shao Y et al. (eds). Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103: 1-12.
4. Ollendorf DA, Hayes J, McMahon P et al. (eds). Management Options for Low-Risk Prostate Cancer: A Report on Comparative Effectiveness and Value. Institute for Clinical and Economic Review, Massachusetts General Hospital: Boston, MA 2010; pp. 5-76.
5. Penson DF, Chan JM. Urologic Diseases in America Project. Prostate cancer. J Urol 2007; 177: 2020-2029.
6. Swanson GP, Riggs MW, Earle JD, Haddock MG. Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol 2002; 42: 212-216.
7. Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565.
8. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007; 25: 110-114.
9. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930.
10. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578.
11. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335.
12. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962.
13. Ghia AJ, Shrieve DC, Tward JD. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology 2010; 76: 1169-1174.
14. Hoffman KE, Nguyen PL, Chen MH et al. Recommendations for postprostatectomy radiation therapy in the United States before and after the presentation of randomized trial. J Urol 2011; 185(1): 116-120.
15. Schreiber D, Rineer J, Yu JB et al. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 2010; 116: 5757-5766.
16. Nielsen ME, Trock BJ, Walsh PC. Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Netw 2010; 8: 228-237.
17. Trabulsi EJ, Valicenti RK, Hanlon AL et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008; 72: 1298-1302.
18. Budiharto T, Perneel C, Haustermans K et al. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 2010; [Epub ahead of print].
19. Fleming C, Wasson JH, Albertsen PC et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 1993; 269: 2650-2658.
20. Konski A, Speier W, Hanlon AL et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007; 25: 3603-3608.
21. Konski A, Watkins-Bruner D, Feigenberg S et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 408-415.
22. Zubek VB, Konski A. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. Mol Diag Ther 2009; 13: 31-47.
23. Swanson GP, Hussey MA, Tangen CM et al. Predominant treatment failure pattern in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007; 25: 2225-2229.
24. Thompson IM, Tangen CM, Klein EA. Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol 2009; 27: 2898-2899.
25. Agarwal PK, Sadetsky N, Konety BR et al. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008; 112: 307-314.
26. Grossfeld GD, Stier DM, Flanders SC et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol 1998; 160: 1398-1404.
27. Mehta SS, Lubeck DP, Sadetsky N et al. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004; 171: 215-219.
28. Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol 2005; 23: 8204-8211.
29. Weinstein MC, O'Brien B, Horberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 64: 9-17.
30. Feng M, Hanlon AL, Pisansky TM et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1417-1423.
31. Krupski TL, Foley KA, Baser O et al. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007; 178: 1423-1428.
32. Frizzera C, Sebelius K. Medicare Program: changes to the hospital outpatient prospective payment system and CY 2010 payment rates; changes to the ambulatory surgical center payment system and CY 2010 payment rates. Final rule with comment period. Fed Regist 2009; 74: 60315-60983.
33. TreeAge Pro 2009 Suite [Computer Program]. In Edition 1.0.2. Williamstown, MA: TreeAge Software, Inc. 2009.
34. Sanguineti G, Castellone P, Foppiano F et al. Anatomic variations due to radical prostatectomy: impact on target volume definition and dose-volume parameters of rectum and bladder. Strahlenther Onkol 2004; 180: 563-572.
35. Chen JC, Schultheiss TE, Nguyen KH, Wong JY. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 71: 351-357.
36. Teh BS, Wei-Yuan M, Augspurger ME et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 2001; 49: 465-472.
37. Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-2769.
38. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
39. Raldow A, Hamstra DA, Kim SN, Yu JB. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev 2011; 37: 89-96.